trending Market Intelligence /marketintelligence/en/news-insights/trending/gjgU_7tgenSyRlo0nAmPKQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Chiasma resubmits application for hormonal disorder drug in US

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Chiasma resubmits application for hormonal disorder drug in US

Chiasma Inc. said it resubmitted a new drug application for Mycapssa in the U.S.

The Waltham, Mass.-based biopharmaceutical company is seeking the U.S. Food and Drug Administration's approval to market Mycapssa as a maintenance treatment for adults with acromegaly, a hormonal disorder that causes an increase in the size of bones of the hands, feet and face. Maintenance therapy is an add-on treatment meant to bolster the main therapy.

Chiasma said in a Jan. 10 press release that its application was backed by positive data from a phase 3 trial, dubbed Chiasma Optimal.

The company said it expects a six-month review of the filing and expects a decision by the FDA by mid-year and hopes to bring the product to the market during the fourth quarter of 2020.

Chiasma also expects to report results from an international phase 3 trial of Mycapssa — called Mpowered — to support the drug's approval in the EU.